Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial

149Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Everolimus is a proliferation signal inhibitor with immunosuppressive activity that may reduce the rate of progression of chronic rejection, bronchiolitis obliterans syndrome (BOS), after lung transplantation. In a randomized, double-blind clinical trial, 213 BOS-free maintenance patients received everolimus (3 mg/day) or azathioprine (AZA, 1-3 mg/kg/day) in combination with cyclosporine and corticosteroids. The prospectively defined primary endpoint was the incidence of efficacy failure (decline in FEV 1 >15%[ΔFEV1 >15%], graft loss, death or loss to follow-up) at 12 months. Incidence of efficacy failure at 12 months was significantly lower in the everolimus group than AZA (21.8% vs. 33.9%; p = 0.046); at 24 months, rates of efficacy failure became similar between the groups. At 12 months, the everolimus group had significantly reduced incidences of ΔFEV1 >15%, ΔFEV1 >15% with BOS, and acute rejection. At 24 months, only incidence of acute rejection remained significantly less in the everolimus group. Treatment discontinuations (particularly due to adverse events), serious adverse events and high serum creatinine values were more common with everolimus. For the first time, a drug has demonstrated significant slowing of loss in lung function, suggesting that patients kept on prolonged maintenance treatment with everolimus may benefit from replacing AZA with everolimus 3 months after lung transplantation. © 2005 The American Society of Transplantation and the American Society of Transplant Surgeons.

References Powered by Scopus

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

0
2965Citations
N/AReaders
Get full text

Bronchiolitis obliterans syndrome 2001: An update of the diagnostic criteria

1182Citations
N/AReaders
Get full text

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1072Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Obliterative bronchiolitis

246Citations
N/AReaders
Get full text

Rapamycin: Something old, something new, sometimes borrowed and now renewed

212Citations
N/AReaders
Get full text

Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation

204Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Snell, G. I., Valentine, V. G., Vitulo, P., Glanville, A. R., McGiffin, D. C., Loyd, J. E., … Pirron, U. (2006). Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial. American Journal of Transplantation, 6(1), 169–177. https://doi.org/10.1111/j.1600-6143.2005.01134.x

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 21

62%

Researcher 9

26%

Professor / Associate Prof. 3

9%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 33

77%

Nursing and Health Professions 4

9%

Agricultural and Biological Sciences 4

9%

Pharmacology, Toxicology and Pharmaceut... 2

5%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free